Fisher Asset Management LLC Acquires 195,094 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN)

Fisher Asset Management LLC boosted its holdings in shares of Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 47.8% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 602,842 shares of the company's stock after acquiring an additional 195,094 shares during the quarter. Fisher Asset Management LLC owned 0.66% of Myriad Genetics worth $16,512,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of MYGN. Vanguard Group Inc. grew its holdings in shares of Myriad Genetics by 0.8% during the 1st quarter. Vanguard Group Inc. now owns 10,035,708 shares of the company's stock valued at $213,961,000 after acquiring an additional 81,475 shares in the last quarter. American International Group Inc. raised its holdings in Myriad Genetics by 6.8% during the first quarter. American International Group Inc. now owns 47,331 shares of the company's stock valued at $1,009,000 after buying an additional 3,011 shares in the last quarter. CANADA LIFE ASSURANCE Co boosted its stake in shares of Myriad Genetics by 7.4% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 103,498 shares of the company's stock worth $2,204,000 after acquiring an additional 7,123 shares in the last quarter. Lazard Asset Management LLC boosted its position in Myriad Genetics by 74.6% during the first quarter. Lazard Asset Management LLC now owns 21,143 shares of the company's stock worth $449,000 after purchasing an additional 9,036 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its holdings in shares of Myriad Genetics by 13.4% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 53,568 shares of the company's stock worth $1,143,000 after buying an additional 6,337 shares during the period. Hedge funds and other institutional investors own 99.02% of the company's stock.

Insider Buying and Selling

In other Myriad Genetics news, CEO Paul J. Diaz sold 15,000 shares of the company's stock in a transaction that occurred on Friday, October 11th. The shares were sold at an average price of $22.93, for a total value of $343,950.00. Following the completion of the sale, the chief executive officer now owns 962,378 shares of the company's stock, valued at approximately $22,067,327.54. This represents a 1.53 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Colleen F. Reitan sold 46,012 shares of Myriad Genetics stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $27.95, for a total transaction of $1,286,035.40. Following the transaction, the director now directly owns 42,533 shares in the company, valued at approximately $1,188,797.35. This represents a 51.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 71,012 shares of company stock valued at $1,900,485 over the last ninety days. Insiders own 2.10% of the company's stock.

Analyst Upgrades and Downgrades

MYGN has been the subject of several research analyst reports. Scotiabank boosted their price objective on Myriad Genetics from $29.00 to $34.00 and gave the stock a "sector outperform" rating in a research report on Tuesday, August 13th. JPMorgan Chase & Co. raised their price objective on shares of Myriad Genetics from $17.00 to $20.00 and gave the stock an "underweight" rating in a research note on Wednesday, August 7th. StockNews.com cut shares of Myriad Genetics from a "buy" rating to a "hold" rating in a research note on Wednesday, November 20th. Piper Sandler decreased their price target on shares of Myriad Genetics from $30.00 to $24.00 and set a "neutral" rating on the stock in a research report on Monday, November 11th. Finally, Morgan Stanley cut their price objective on shares of Myriad Genetics from $32.00 to $21.00 and set an "equal weight" rating for the company in a research report on Monday, November 18th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $27.36.

Myriad Genetics Trading Up 0.7 %

Myriad Genetics stock traded up $0.11 during mid-day trading on Thursday, hitting $16.28. The stock had a trading volume of 713,467 shares, compared to its average volume of 745,519. The company has a current ratio of 1.90, a quick ratio of 1.73 and a debt-to-equity ratio of 0.05. Myriad Genetics, Inc. has a 12 month low of $14.72 and a 12 month high of $29.30. The stock has a market capitalization of $1.48 billion, a PE ratio of -12.52 and a beta of 1.93. The stock has a 50-day simple moving average of $21.52 and a two-hundred day simple moving average of $24.30.

Myriad Genetics Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.